TIRBANIBULIN

/static/temp/default.svg

Search structure


Synonyms	KX-01 KX-2-391 KX-2391 KX2-391 KX2391 Klisyri Kx2-391 Tirbanibulin
Status
Molecule Category	UNKNOWN
ATC	D06BX03
UNII	4V9848RS5G
EPA CompTox	DTXSID30237862


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HUNGUWOZPQBXGX-UHFFFAOYSA-N
Smiles	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1
InChI	InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H29N3O3
Molecular Weight	431.54
AlogP	3.32
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	9.0
Polar Surface Area	63.69
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	32.0

Bioactivity

Mechanism of Action	Action	Reference
Tyrosine-protein kinase SRC inhibitor	INHIBITOR	PubMed PubMed Other DOI


Protein: Tyrosine-protein kinase SRC Description: Proto-oncogene tyrosine-protein kinase Src Organism : Homo sapiens P12931 ENSG00000197122

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Kinase Protein Kinase Atypical protein kinase group Atypical protein kinase BCR family	-	100	-	-	-
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Abl family	-	100	-	-	-
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Src family	-	7-67000	-	-	-
Other cytosolic protein	-	100	-	-	-

Assay Description	Organism	Bioactivity	Reference
Inhibition of c-SRC	None	20.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	79.89 %
Antiproliferative activity against human HT-29 cells in presence of 1.5% FCS by BrdU incorporation assay	Homo sapiens	23.0 nM
Inhibition of human c-SRC expressed in mouse NIH/3T3 cells assessed as inhibition of cell growth in presence of 1.5% FCS by BrdU incorporation assay	Homo sapiens	13.0 nM
Antiproliferative activity against human HT-29 cells in presence of 0.5% FCS	Homo sapiens	5.0 nM
Inhibition of human c-SRC expressed in mouse NIH/3T3 cells assessed as inhibition of cell growth in presence of 0.5% FCS	Homo sapiens	6.5 nM
Inhibition of BCR/ABL (unknown origin)	Homo sapiens	100.0 nM
Inhibition of LYN (unknown origin)	Homo sapiens	100.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	1.114 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.68 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.68 %
Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	Homo sapiens	18.2 nM
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	Homo sapiens	6.8 nM
Antiproliferative activity against human Ramos cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	Homo sapiens	15.7 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL571546
DrugBank	DB06137
FDA SRS	4V9848RS5G
Guide to Pharmacology	7957
PDB	DN0
PubChem	23635314
SureChEMBL	SCHEMBL153779
ZINC	ZINC000043152787

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).